Forum Financial Management LP Increases Stock Position in Eli Lilly and Company (NYSE:LLY) (2024)

Forum Financial Management LP increased its position in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 0.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,073 shares of the company’s stock after acquiring an additional 55 shares during the quarter. Forum Financial Management LP’s holdings in Eli Lilly and Company were worth $4,873,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of LLY. Baystate Wealth Management LLC increased its stake in Eli Lilly and Company by 688.2% during the 2nd quarter. Baystate Wealth Management LLC now owns 3,736 shares of the company’s stock valued at $1,752,000 after purchasing an additional 3,262 shares in the last quarter. Simon Quick Advisors LLC lifted its holdings in Eli Lilly and Company by 13.0% during the second quarter. Simon Quick Advisors LLC now owns 1,874 shares of the company’s stock valued at $879,000 after purchasing an additional 215 shares in the last quarter. Physicians Financial Services Inc. lifted its holdings in Eli Lilly and Company by 1.9% during the second quarter. Physicians Financial Services Inc. now owns 2,718 shares of the company’s stock valued at $1,275,000 after purchasing an additional 50 shares in the last quarter. HF Advisory Group LLC lifted its holdings in Eli Lilly and Company by 4.9% during the second quarter. HF Advisory Group LLC now owns 3,629 shares of the company’s stock valued at $1,702,000 after purchasing an additional 170 shares in the last quarter. Finally, Rooted Wealth Advisors Inc. purchased a new position in Eli Lilly and Company during the second quarter valued at $220,000. Institutional investors own 81.38% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of LLY stock traded up $4.27 during trading hours on Wednesday, hitting $633.95. The stock had a trading volume of 2,275,751 shares, compared to its average volume of 2,982,496. The firm has a market capitalization of $601.82 billion, a PE ratio of 114.85, a PEG ratio of 2.03 and a beta of 0.31. Eli Lilly and Company has a twelve month low of $309.20 and a twelve month high of $647.73. The stock’s 50 day moving average is $599.44 and its 200 day moving average is $561.93. The company has a debt-to-equity ratio of 1.59, a current ratio of 1.05 and a quick ratio of 0.82.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last posted its quarterly earnings data on Thursday, November 2nd. The company reported $0.10 earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.18. The business had revenue of $9.50 billion during the quarter, compared to the consensus estimate of $8.88 billion. Eli Lilly and Company had a return on equity of 48.12% and a net margin of 15.55%. As a group, research analysts forecast that Eli Lilly and Company will post 6.54 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, March 4th. Investors of record on Thursday, February 15th will be issued a dividend of $1.30 per share. The ex-dividend date of this dividend is Wednesday, February 14th. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.13. This represents a $5.20 annualized dividend and a dividend yield of 0.82%. Eli Lilly and Company’s dividend payout ratio (DPR) is currently 81.88%.

Insider Buying and Selling

In related news, CAO Donald A. Zakrowski sold 670 shares of the stock in a transaction on Monday, November 6th. The stock was sold at an average price of $571.10, for a total transaction of $382,637.00. Following the completion of the sale, the chief accounting officer now directly owns 4,708 shares of the company’s stock, valued at $2,688,738.80. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 1,180 shares of the stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $645.60, for a total value of $761,808.00. Following the completion of the transaction, the insider now owns 99,542,630 shares in the company, valued at $64,264,721,928. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Donald A. Zakrowski sold 670 shares of the firm’s stock in a transaction on Monday, November 6th. The shares were sold at an average price of $571.10, for a total value of $382,637.00. Following the completion of the transaction, the chief accounting officer now owns 4,708 shares of the company’s stock, valued at approximately $2,688,738.80. The disclosure for this sale can be found here. Insiders sold a total of 63,120 shares of company stock valued at $39,862,068 over the last three months. 0.13% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. UBS Group restated a “buy” rating and set a $710.00 price objective (up from $612.00) on shares of Eli Lilly and Company in a research report on Friday, October 20th. TheStreet cut shares of Eli Lilly and Company from a “b” rating to a “c+” rating in a research report on Monday, December 4th. Truist Financial reiterated a “buy” rating and set a $650.00 price target on shares of Eli Lilly and Company in a research report on Wednesday, November 29th. Barclays lifted their price target on shares of Eli Lilly and Company from $630.00 to $680.00 and gave the company an “overweight” rating in a research report on Tuesday. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $630.00 price target on shares of Eli Lilly and Company in a research report on Tuesday. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seventeen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $589.90.

View Our Latest Analysis on LLY

Eli Lilly and Company Company Profile

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.